Brentuximab for CD30-positive mesothelioma that can’t be removed
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests brentuximab vedotin, a drug targeting a marker called CD30, in people with malignant mesothelioma that cannot be removed with surgery. It may help shrink the tumor or control the disease when other treatments are limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of malignant mesothelioma that cannot be removed by surgery
- Your tumor test must show CD30 positivity (CD30+ on lab testing)
- Your scans must show measurable disease within 28 days of starting the study
- Your blood counts and organ function must be high enough (white blood cells, platelets, hemoglobin, bilirubin, liver enzymes, and kidney function)
- You must be well enough to do daily activities (ECOG score 0–2)
- You must use reliable birth control or avoid heterosexual sex during the study and for months after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antibody therapy and immunotherapy (plus standard chemo) as first treatment for primary mediastinal large B-cell lymphoma. It may help shrink the lymphoma and improve how long patients stay in remission.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
This trial studies whether brentuximab vedotin given in the “second-line” setting can help people with relapsed or hard-to-treat classic Hodgkin lymphoma get ready for an autologous (your own cells) stem cell transplant. It’s specifically for tumors that test positive for CD30, and it checks safety and how well treatment works before transplant.
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
This trial tests a combination of two drugs for people with a specific type of skin lymphoma. Brentuximab vedotin targets a protein called CD30 on lymphoma cells, and lisaftoclax helps destroy those cells. The goal is to see if this combination is safe and effective.
Hear when a new CD30-Positive Neoplastic Cells Present trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.